Successful salvage high-dose chemotherapy and autologous stem-cell transplantation in HIV-related germ-cell tumor

Hentrich, M.; Schiel, Xaver; Niedermeier, A.; Lutz, Ludwig; Rupec, Rudolf A.; Stief, Christian G.; Bogner, Johannes R.; Karthaus, Meinolf; Gerl, Arthur

doi:10.1093/annonc/mdp448

Cited by 4 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although data on the treatment of relapsed disease are very limited, patients should be treated in an identical manner to HIV-negative patients [27][28][29]. If indicated, high-dose chemotherapy followed by autologous stem cell transplantation can be offered to HIV-infected patients with GCC [32].…”

Section: Treatmentmentioning

confidence: 99%

HIV-Associated Urogenital Malignancies

Hentrich

Pfister

2017

Oncol Res Treat

View full text Add to dashboard Cite

Non-AIDS-defining malignancies (NADM) are a leading cause of morbidity and mortality for HIV-infected subjects. The risk of testicular germ cell cancer (GCC) and renal cell cancer is slightly increased in the setting of HIV, whereas there is a slightly decreased risk of prostate cancer and bladder cancer. As in industrialized countries the majority of people living with HIV are men, and people aged 55 and older now account for more than a quarter of persons living with HIV, both testis and prostate cancer are assumed to occur with increased frequency in HIV-infected subjects. Overall, treatments should be the same as in HIV-negative patients with urogenital malignancies. Since the introduction of combination antiretroviral therapy (cART) the outcome appears to have improved due to a decrease in HIV-related deaths. HIV-infected men who are treated with standard therapies for GCC now have a similar cancer-free survival compared with their HIV-negative counterparts. Screening and treatment for prostate cancer should follow recommendations established for HIV-negative men. During radio- or chemotherapy patients should receive concurrent cART but the drug-drug interaction potential must be taken into account.

show abstract